Business Model & Revenue
Arq sells consumable purification products — primarily powdered activated carbon (PAC), plus granular activated carbon and colloidal carbon products and emission-control additives — to utility, industrial and environmental customers in the United States and Canada. The model is recurring by design: carbon is spent and re-ordered with treatment volumes, and the company's Red River plant turnaround, completed materially under budget in 2026, is the low-cost production base behind the gross margin climb from 28.8% to 39.7%.
Formerly Advanced Emissions Solutions, Arq built its base in utility air compliance and is pivoting the same customer relationships into water treatment. The next leg is PAC for PFAS, a patent-pending product line engineered to help water utilities near the EPA's 4-parts-per-trillion PFAS threshold comply without the capital cost of new GAC contactors; initial customer testing is complete with further testing through year-end and orders feasible in 2027 as the April 2027 EPA monitoring-and-reporting deadline approaches. The Corbin Facility and its related technologies — including asphalt additives in expanded testing with a leading U.S. asphalt company — are held as monetization optionality rather than core operations.
Financial Highlights
Q3 2026 Results (Quarter Ended September 30, 2026)
| Metric | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Revenue | $38.2M | $35.0M | +9% |
| Gross margin | 39.7% | 28.8% | +1,090 bps |
| Net income | $2.5M | $(0.9)M adj. | First GAAP profit of 2026 |
| Diluted EPS | $0.06 | $(0.02) adj. | Beat $0.04 consensus |
| Adjusted EBITDA | $8.8M | $5.2M | +71% |
| Operating cash flow (9M) | $7.7M | $0.03M adj. | Inflection |
Q3 2026 vs Consensus
| Metric | Reported | Consensus | Beat |
|---|---|---|---|
| Revenue | $38.2M | $35.25M | +8.4% |
| EPS | $0.06 | $0.04 | +50% |
Quarterly Progression
| Quarter | Revenue | Net Income | Adjusted EBITDA | Gross Margin |
|---|---|---|---|---|
| Q4 2025 | $29.4M | n/d | n/d | n/d |
| Q1 2026 | $29.0M | n/d | n/d | n/d |
| Q2 2026 | $29.9M | $(0.7)M | $5.8M | 38.5% |
| Q3 2026 | $38.2M | $2.5M | $8.8M | 39.7% |
Q1 2026 derived from nine-month disclosure of $97.1M less Q2 and Q3.
Annual Context
| Metric | FY 2025 | FY 2024 | 9M 2026 | 9M 2025 |
|---|---|---|---|---|
| Revenue | $120.3M | $109.0M | $97.1M | $90.9M |
| Net income | $(52.6)M | n/d | $0.6M | $(3.3)M adj. |
Balance Sheet Snapshot (September 30, 2026)
| Item | Amount |
|---|---|
| Cash (incl. restricted) | $19.1M ($11.3M restricted) |
| Debt incl. financing leases | $28.2M (from $30.7M at Jun 30) |
| Shares outstanding | 44.17M (vs 42.73M at Dec 31) |
Guidance: FY2026 revenue reiterated at $120-125 million; Adjusted EBITDA guidance raised to $19-20 million from $17-20 million; capex of $8-10 million reiterated.
Competitive Landscape
Arq operates in the fragmented global activated carbon market, where a handful of larger producers dominate commodity GAC while Arq competes primarily in North American PAC for utility and industrial water and air treatment. Scale producers hold purchasing and logistics advantages; Arq's edge is furnace-level cost efficiency and application engineering on its home continent.
- Kuraray / Calgon Carbon (TSE:3405): the global activated carbon leader following Kuraray's acquisition of Calgon; deepest product portfolio and international footprint, but higher-cost Western production base.
- Cabot Corporation (CBT): U.S.-listed specialty chemicals major with a large activated carbon business; far greater balance sheet and R&D resources across purification end markets.
- Osaka Gas Chemicals / Jacobi Carbons: Japan-backed global GAC producer strong in water and purification markets; competes on price in imported product.
- Haycarb (Sri Lanka): one of the largest coconut-shell activated carbon producers; aggressive pricing pressure in commodity grades sold into the Americas.
- Ingevity (NGVT): U.S. public neighbor in specialty carbons for treatment applications; larger and more diversified, but wrestling with its own end-market softness.
Moats: (1) a Red River production base that just delivered a sub-$8.8 million EBITDA quarter on $38 million of revenue after an under-budget turnaround; (2) ten consecutive quarters of positive Adjusted EBITDA through a brutal pricing cycle; (3) patent-pending PAC for PFAS products that retrofit into utilities' existing PAC feed systems ahead of an EPA compliance deadline; (4) entrenched utility customer relationships built over three decades in emissions compliance.
Catalysts
- Q4 2026 earnings (early March 2027): delivery on the raised $19-20 million Adjusted EBITDA guide and any initial FY2027 outlook; consensus already sits at Strong Buy with a $4.03 average target.
- PAC for PFAS commercialization: customer testing concludes around year-end 2026 and orders are feasible in 2027 as the EPA's April 2027 monitoring-and-reporting deadline forces utility compliance spending — the single biggest upside lever to volumes and pricing.
- Corbin Facility monetization: active discussions with multiple parties plus expanded asphalt testing with a leading U.S. asphalt company; a sale would clean up the balance sheet and validate the technology portfolio.
- Red River furnace efficiency program: identified throughput and unit-cost improvements that management expects to compound margins into 2027.
- Deleveraging trajectory: debt including financing leases fell $2.5 million in the quarter to $28.2 million; continued paydown narrows the equity story to a clean EBITDA compounder.
Key Risks
- Liquidity and restricted cash: only $7.8 million of the $19.1 million quarter-end cash was unrestricted, against $8-10 million of full-year capex guidance and $28.2 million of debt including financing leases — a demand air pocket would force renewed borrowing or dilutive equity at micro-cap pricing.
- Dilution risk: shares outstanding rose 3.4% in nine months to 44.17 million, the company has a multi-year history of issuance after a FY2025 net loss of $52.6 million, and any acceleration of PFAS commercialization spending would likely be funded with more equity.
- End-market concentration and seasonality: the core powdered activated carbon business leans on utility and industrial treatment demand, Q3 is seasonally the strongest quarter (management's own characterization), and Q4 2026 revenue faces a tough sequential comparison against $38.2 million.
- PFAS adoption risk: initial customer testing of PAC for PFAS is complete but meaningful orders are described as feasible only in 2027; the EPA's April 2027 monitoring-and-reporting deadline could be revised or its scope narrowed, and pending patents may never issue.
- Corbin monetization and cost creep: discussions with multiple parties remain uncommitted and could stall while the facility consumes carrying costs, and Q3 SG&A jumped 56% year over year to $7.2 million, which would erode margins if revenue growth stalls.
Our Thesis
Arq is a rare micro-cap turnaround where the dirty work is already done. The stock has fallen 71% from its 52-week high of $6.60, priced on a FY2025 net loss of $52.6 million and years of issuance rather than on the 2026 inflection: gross margin has climbed from 28.8% to 39.7% year over year, nine-month operating cash flow reached $7.7 million against roughly zero a year ago, and the Red River plant turnaround finished materially under budget. Two unpriced options sit on top: PAC for PFAS, whose initial customer testing is complete ahead of the EPA's April 2027 utility monitoring deadline, and the Corbin Facility, in monetization talks with multiple parties with asphalt testing expanded.
At $2.31, Arq's market cap is approximately $102 million on 44.17 million shares; enterprise value is roughly $111 million after $28.2 million of debt less $19.1 million of cash — 5.7x the $19.5 million midpoint of guided FY2026 Adjusted EBITDA, versus 9-11x for diversified treatment peers. Our $3.25 target is probability-weighted: 45% at $4.13 (8.5x FY2027 EBITDA of $23 million with PFAS adoption), 45% at $2.87 (7x guided 2026 EBITDA), 10% at $1.60 (demand slump and dilution) = $3.32, call it $3.25.
Get reports like this delivered free
New small-cap research every week. No paywall, no fluff.